AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1838079
Drug: 17 beta‐oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 beta‐oestradiol 1.5 mg on days 1‐12 and 17 beta‐oestradiol 1.5 mg + desogestrel 150 micrograms on days 13‐24 (E2/DG)
Trial: 1838079
Drug: oestradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oestradiol valerate 2 mg on days 1‐11 and oestradiol valerate 2 mg + medroxyprogesterone acetate 10 mg on days 12‐21 (E2V/MPA)
Trial: 7193582
Drug: Phenylpropanolamine, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine, 50 mg twice daily
Trial: 20231319
Drug: Meta-cognitive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meta-cognitive therapy
Trial: 26109630
Drug: S-1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 plus irinotecan (oral S-1 40-60 mg/m² on days 1-14 and intravenous irinotecan 150 mg/m² on day 1 of a 21-day cycle)
Trial: 26109630
Drug: irinotecan-alone (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan-alone (intravenous irinotecan 150 mg/m² on day 1 of a 14-day cycle)
Trial: 23637556
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg + Hydrochlorothiazide 25 mg (T80/H25)
Trial: 23637556
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg (T80)
Trial: 16678551
Drug: Sibutramine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine (15 mg per day for 5 days)
Trial: 15225889
Drug: Nicotine pretreatment
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine pretreatment via a transdermal patch (21 mg)
Trial: 15225889
Drug: Ethanol administration
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol administration (0.4 and 0.7 g/kg)
Trial: 11295031
Drug: Standard dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dialysis dose
Trial: 11295031
Drug: Higher dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dialysis dose
Trial: 9207355
Drug: Sorivudine 40
RxNorm normalized name: Brivudine
DrugBank: Brivudine (DB03312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorivudine 40 mg once daily for 7 days
Trial: 30113736
Drug: 2% triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% triple antibiotic paste (TAP)
Trial: 30113736
Drug: 100% triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% triple antibiotic paste (TAP)
Trial: 24458199
Drug: 300-mg sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300-mg sustained-release tablet (SRT) of ONO-5334
Trial: 24458199
Drug: Repeated dosing
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated dosing of 300-mg sustained-release tablet (SRT) of ONO-5334
Trial: 24458199
Drug: 300-mg immediate-release
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300-mg immediate-release tablet (IRT) of ONO-5334
Trial: 21435695
Drug: Diuretic initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Diuretic initiation
Trial: 21435695
Drug: Diuretic discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic discontinuation
Trial: 16814206
Drug: HPV testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV testing (> or = 1 pg/mL) with cytology triage
Trial: 12763513
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral hormone replacement therapy (HRT)
Trial: 8868968
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy with adolescents
Trial: 1658652
Drug: Ganciclovir (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir (5 mg/kg twice a day for one week, followed by 5 mg/kg per day)
Trial: 6350071
Drug: Tioconazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tioconazole 1% cream applied twice daily for 14 days (pityriasis versicolor) or 28 days (dermatophyte and yeast infections)
Trial: 6350071
Drug: Miconazole 2%
RxNorm normalized name: MICONAZOLE 200MG SUPP/MICONAZOLE 2% CREAM PAK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miconazole 2% cream applied twice daily for 14 days (pityriasis versicolor) or 28 days (dermatophyte and yeast infections)
Trial: 24206639
Drug: Cognitive remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation treatment
Trial: 27508536
Drug: Racecadotril (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racecadotril (1.5 mg/kg/dose, thrice a day for three days)
Trial: 17634494
Drug: Ifosfamide 9
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide 9 g/m2 over 3 days continuous infusion
Trial: 17634494
Drug: Ifosfamide 3
RxNorm normalized name: ifosfamide 3000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 3 g/m2 per day in 3 hours over 3 days
Trial: 17634494
Drug: Standard doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doxorubicin 75 mg/m2 every 21 days
Trial: 14691439
Drug: Tirofiban +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban + heparin
Trial: 11720197
Drug: Combined hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormone replacement therapy regimens (estrogen plus different progestogens)
Trial: 11720197
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy alone
Trial: 11720197
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy for secondary prevention
Trial: 9779765
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil oral suspension (10 mg/kg) administered in fed condition
Trial: 9779765
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil oral suspension (10 mg/kg) administered in fasted condition
Trial: 2577461
Drug: Benzothiadiazine diuretic
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzothiadiazine diuretic agents
Trial: 2577461
Drug: Beta-adrenergic receptor-blocking
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenergic receptor-blocking drugs
Trial: 2577461
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of both drug classes
Trial: 28470550
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution infused at a rate of 125 mL/h
Trial: 28470550
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution infused at a rate of 250 mL/h
Trial: 28470550
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution boosted with 5% glucose, infused at a rate of 125 mL/h
Trial: 24229674
Drug: Enteric-coated lumbrokinase
RxNorm normalized name: lumbrokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated lumbrokinase capsules plus standard stroke treatment
Trial: 19666939
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of oral calcium supplement, daily, for 8 weeks
Trial: 15288159
Drug: Flecainide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (2 mg/kg body weight, maximum 200 mg, given over 20 min)
Trial: 15288159
Drug: Ibutilide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide (1 mg or 0.01 mg/kg if less than 60 kg, infused over 10 min)
Trial: 15288159
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Flecainide and Ibutilide)
Trial: 11288049
Drug: high‐vegetable, fruit,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high‐vegetable, fruit, and nut diet (very‐high‐fiber, 55 g/1,000 kcal)
Trial: 8210613
Drug: Nicotine chewing
RxNorm normalized name: nicotine Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine chewing gum (4 mg)
Trial: 3709026
Drug: Nicotine chewing
RxNorm normalized name: nicotine Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine chewing gum (2 or 4 mg)
Trial: 26961367
Drug: Patient-initiated model
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-initiated model of care for botulinum toxin treatment
Trial: 26961367
Drug: Standard model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard model of care for botulinum toxin treatment
Trial: 22761191
Drug: Sublingual extract
RxNorm normalized name: Timothy grass pollen extract Sublingual Tablet [Grastek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual extract of rye grass for 6 months
Trial: 20367777
Drug: PDE5 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PDE5 inhibitors plus regular physical activity (≥3 hours/week)
Trial: 20367777
Drug: PDE5 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PDE5 inhibitors alone
Trial: 20367777
Drug: PDE5 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PDE5 inhibitors plus physical activity
Trial: 16043199
Drug: 3 mg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg.kg(‐1) day(‐1) caffeine intake (G3)
Trial: 16043199
Drug: 0 mg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg.kg(‐1) day(‐1) caffeine intake (G0)
Trial: 16043199
Drug: 6 mg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg.kg(‐1) day(‐1) caffeine intake (G6)
Trial: 760698
Drug: Synthetic salmon
RxNorm normalized name: Synthetic salmon calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic salmon calcitonin administered subcutaneously
Trial: 760698
Drug: Synthetic salmon
RxNorm normalized name: Synthetic salmon calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic salmon calcitonin administered in the evening
Trial: 25111539
Drug: neostigmine 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neostigmine 70 μg/kg
Trial: 17318498
Drug: Intravenous glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous glutamine supplementation (alanyl-glutamine) for 20 hours
Trial: 17318498
Drug: Intravenous glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous glutamine supplementation (alanyl-glutamine)
Trial: 14749232
Drug: Formula containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula containing 1 x 10(7) CFU/g each of Bifidobacterium lactis and Streptococcus thermophilus
Trial: 14749232
Drug: Formula containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula containing 1 x 10(6) CFU/g each of Bifidobacterium lactis and Streptococcus thermophilus
Trial: 9005964
Drug: Peripheral parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral parenteral nutrition (PPN) alone (n = 6)
Trial: 9005964
Drug: PPN +
RxNorm normalized name: Phenylpropanolamine
DrugBank: Phenylpropanolamine (DB00397)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PPN + recombinant human growth hormone (rGH) at a daily dose of 0.15 U x kg(‐1) x d(‐1) (n = 6)
Trial: 3299095
Drug: Combination amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination amphotericin B and flucytosine for four weeks
Trial: 3299095
Drug: Combination amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination amphotericin B and flucytosine for six weeks
Trial: 24142329
Drug: Epsilon-aminocaproic acid
RxNorm normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epsilon-aminocaproic acid (EACA) 150 mg kg(‐1) intravenously prior to incision, followed by 15 mg kg(‐1) h(‐1) infusion until 2 h after graft reperfusion
Trial: 23578722
Drug: R-CHOP14 (rituximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP14 (rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m², prednisone 40 mg/m² daily for 5 days, administered every 14 days)
Trial: 23578722
Drug: R-CHOP21 (rituximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP21 (rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m², prednisone 40 mg/m² daily for 5 days, administered every 21 days)
Trial: 20053539
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (risperidone, olanzapine, quetiapine IR, ziprasidone, risperidone consta, aripiprazole, paliperidone, quetiapine XR)
Trial: 20053539
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment vs Placebo
Trial: 17965045
Drug: Repetitive activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive activities of daily living (ADL) activity programme
Trial: 16868539
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (CT) - cisplatin (50 mg m(‐2)), doxorubicin (45 mg m(‐2)), cyclophosphamide (600 mg m(‐2)) every 28 days for five cycles
Trial: 12859554
Drug: Capsaicin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin (5 treatments on the first day at 1-hour intervals)
Trial: 12859554
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 treatments on the first day)
Trial: 8878099
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg melatonin with placebo
Trial: 8878099
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg melatonin with 10 mg flumazenil
Trial: 29055953
Drug: Minoxidil 5%
RxNorm normalized name: MINOXIDIL 5% SOLN,TOP
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minoxidil 5% solution
Trial: 27600184
Drug: Glucose added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose added to fructose in solution
Trial: 11916175
Drug: Azithromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1 g orally as a single dose)
Trial: 19438399
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg orally twice a day for 7 days)
Trial: 16705448
Drug: 0.5 mg/ml
RxNorm normalized name: urea 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/ml ICG staining
Trial: 16705448
Drug: 1.25 mg/ml
RxNorm normalized name: menthol 1.25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg/ml ICG staining
Trial: 15476576
Drug: Pamidronate (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (60 mg intravenously administered 14 days before bed rest)
Trial: 9562008
Drug: Perindopril (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (2 to 8 mg/day)
Trial: 9562008
Drug: Hydrochlorothiazide (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (12.5 to 50 mg/day) plus Amiloride (1.25 to 5 mg/day)
Trial: 3107514
Drug: L-deprenyl 10
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-deprenyl 10 mg/d
Trial: 3107514
Drug: L-deprenyl 40
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-deprenyl 40 mg/d
Trial: 31389750
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser irradiation (LLLI) applied to one of the two implants (940-nm wavelength, 0.50 ± 2 mW output power, 0.004 cm2 spot size; total delivered energy of 90 J in 3 sessions)
Trial: 22030858
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of pivmecillinam treatment
Trial: 22030858
Drug: 3 days
RxNorm normalized name: Transderm Scop 1mg/3 days Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 days of pivmecillinam treatment
Trial: 17042148
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg of inhaled budesonide + 5 mg oral montelukast
Trial: 17042148
Drug: 400 microg
RxNorm normalized name: Fentanyl 400 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg of inhaled budesonide
Trial: 12707491
Drug: Intravenous valproate
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous valproate loading
Trial: 12707491
Drug: Oral valproate
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral valproate loading
Trial: 10714048
Drug: Ziprasidone (5-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (5-40 mg/day)
Trial: 8262084
Drug: Atenolol and
RxNorm normalized name: atenolol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol and nifedipine fixed combination
Trial: 3085136
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg fluphenazine decanoate
Trial: 1860020
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg fluphenazine decanoate
Trial: 3085136
Drug: Combined dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined dosage groups (5 mg and 25 mg)
Trial: 26862696
Drug: Palifermin, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palifermin, 60 mg/kg, intravenously as a single dose 3 days before and after transplant conditioning regimen cycle
Trial: 26862696
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo treatment)
Trial: 25229957
Drug: Structural Family
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structural Family Therapy (SFT)
Trial: 8689462
Drug: Intra-articular hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular hyaluronic acid (HA) - 5 injections at weekly intervals
Trial: 8689462
Drug: Intra-articular triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular triamcinolone hexacetonide (TH) - 20 mg followed by 4 placebo (saline) injections
Trial: 698165
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg cyanocobalamin injection, three times weekly for 6 weeks
Trial: 698165
Drug: Placebo injection,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection, three times weekly for 6 weeks
Trial: 21191143
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g essential amino acids with 10 g l-arginine (ARG)
Trial: 15235055
Drug: Intravenous Atrial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Atrial Natriuretic Peptide (ANP)
Trial: 15235055
Drug: Standard conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard conventional therapy (Control)
Trial: 1964599
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral acyclovir therapy for the suppression of recurrent genital herpes simplex virus infection
Trial: 1964599
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral acyclovir therapy
Trial: 377878
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin with regular insulin
Trial: 377878
Drug: PZI insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PZI insulin with regular insulin
Trial: 31860606
Drug: Single-dose stellate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose stellate ganglion block (SGB) with 5 ml of 0.5% ropivacaine
Trial: 31860606
Drug: Single-dose stellate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose stellate ganglion block (SGB)
Trial: 29670279
Drug: F-652 (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F-652 (2.0 µg/kg, SC)